RxDoctor Payments Data

Eric Steffen, MD

Ophthalmology · Lebanon, NHNPI 1376505172

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $135 of the $215 with a category attached, or 62.9%. AbbVie accounts for 65.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $140 and has fallen 77.1% since, to $32 in 2025. That places this record below the midpoint for ophthalmology clinicians in NH, where the typical reported total is $750.

$215in general payments, 2019–2025

Across 5 payments — averaging $43.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$140
  • Johnson & Johnson Surgical Vision, Inc.$43
  • Glaukos Corporation$32

What the payments were for

  • Food & beverage$13563%
  • Education$8037%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$215 in reported general payments places this provider in the 25th percentile of 80 ophthalmology providers in New Hampshire.

See all ophthalmology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$277,900
Medicare patients
703
Services billed
2,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost37$21,041
VyzultaLatanoprostene Bunod33$15,237
Brimonidine Tartrate184$15,177
RhopressaNetarsudil Mesylate26$11,651
Latanoprost887$10,029
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol41$9,798
Brinzolamide33$6,139
Alphagan PBrimonidine Tartrate12$5,701
Timolol Maleate249$4,927
CombiganBrimonidine Tartrate/Timolol12$4,740
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat239$4,416
SimbrinzaBrinzolamide/Brimonidine Tart22$4,355
Cyclosporine14$3,958
Travoprost19$3,014
Prednisolone Acetate65$2,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan$140$31,48161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 80 ophthalmology providers in New Hampshire.

Other ophthalmology in Lebanon

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →